Repros Therapeutics Inc.
Formerly Zonagen, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Repros Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2012).
SEC Form D · Sep 2012
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2012
Products and services#
No products or services on record: its website does not allow automated readers.
Investors#
No investor of Repros Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Joseph S. Podolski | Executive officer | Sep 2012 |
| Katherine S. Anderson | Executive officer | Sep 2012 |
| Daniel S. Cain | Director | Sep 2012 |
| Jaye S. Thompson, Ph.D. | Director | Sep 2012 |
| Jean S. Fourcroy | Director | Sep 2012 |
| Joseph S. Podolski | Director | Sep 2012 |
| Michael S. Wyllie, Ph.D. | Director | Sep 2012 |
| Nola S. Masterson | Director | Sep 2012 |
| Daniel F. Cain | Director | Nov 2009 |
| Jean L. Fourcroy | Director | Nov 2009 |
| Mark S. Lappe | Director | Nov 2009 |
| Nola L. Masterson | Director | Nov 2009 |
About
American pharmaceutical company.